Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Prime Minister Noda Stresses Need for Comprehensive Reform in First Major Policy Speech
September 26, 2011
- METI Seeks Budget to Collect Cancer Tissues, Genetic Data in Fukushima
September 26, 2011
- 6 APIs/10 Products Including EpiPen Added to NHI Price List
September 22, 2011
- Government Designates Fulvestrant as Ad-restricted Drug
September 21, 2011
- HSC Subcommittee Agrees on Need for New System to Promote Access to Unapproved Drugs
September 20, 2011
- Price Settlement Rate Down to 73.9% of Sales in June, Close to Pre-emergency Recommendation Levels
September 19, 2011
- New METI Minister Edano Considers Drug Industry as “Highly Promising Area”
September 19, 2011
- FY2011 White Paper Calls For Reform toward “Participatory” Social Security System
September 19, 2011
- PMDA Expresses Distrust of MSD for Deviations from GCP in Trials of Gardasil
September 19, 2011
- Some Medical Institutions Still Demanding Full Payment, No Refund of Clinical Trial Costs
September 19, 2011
- Discussions Continue on Relief System for Victims of ADRs Due to Anticancer Drugs
September 19, 2011
- Preparations Underway for MHLW to Set Up Private Third-Party Committee
September 16, 2011
- Council Recommends 5 Drugs as Appropriate for Application Based on Info. in Public Domain
September 16, 2011
- US FDA Issues Warning Letter Over GMP Violations by Daiichi Sankyo Subsidiary
September 15, 2011
- MHLW to Survey “Family Pharmacy” Function Toward Next Revision of Dispensing Fees
September 15, 2011
- US Proposes Elimination of Tariff on Drugs: TPP Talks
September 14, 2011
- MHLW to Continue to Promote Non-proprietary Name-based Brand Names for GE Drugs
September 14, 2011
- ”GMP Team” to Begin Mock GMP Inspections in Kinki Region from Next February
September 14, 2011
- MHLW Permits Ongoing Internet Sales of Reclassified Class 2 Drugs as Provisional Measure
September 13, 2011
- MHLW Minister Komiyama to Push Drug Industry Development Through Government-Private Sector Cooperation
September 13, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…